MedTrace Logo

A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland

NCT00623116 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-02-25

No results posted yet for this study

Summary

Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Conditions

  • Kallmann Syndrome

Interventions

DRUG

Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)

clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.

Sponsors & Collaborators

  • Hospital for Children and Adolescents, Finland

    lead OTHER

Principal Investigators

  • Taneli J Raivio, MD PhD · Hospital for Children and Adolescents, Helsinki University Central Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2012-12-31
Completion
2025-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623116 on ClinicalTrials.gov